Sonoma Pharmaceuticals (SNOA) Operating Margin (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Operating Margin of 6.31% for Q1 2026, up 1116.0% year-over-year from 0.52% in Q1 2025, and up 59.51% quarter-over-quarter from 15.59% in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Operating Margin (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Operating Margin history runs 17 years deep, the most recent figure standing at 6.31% for Q1 2026.
- In Q1 2026, Operating Margin rose 1116.0% year-over-year to 6.31%; the TTM figure through Mar 2026 stood at 12.6% (up 1336.0% YoY), while the FY2026 annual figure was 12.6%, up 1336.0% from the prior year.
- Operating Margin for Q1 2026 stood at 6.31%, up from 15.59% in the prior quarter.
- The five-year high for Operating Margin was 6.01% in Q3 2025, with the low at 133.16% in Q1 2022.
- The 5-year median for Operating Margin is 27.27% (2025), against an average of 34.42%.
- The sharpest annual moves came in 2022 and 2023: Operating Margin sank 2928 bps in 2022, then soared 9510 bps in 2023.
- Sonoma Pharmaceuticals' Operating Margin stood at 62.3% in 2022, then soared by 57 bps to 26.9% in 2023, then declined by 8 bps to 28.93% in 2024, then soared by 46 bps to 15.59% in 2025, then surged by 60 bps to 6.31% in 2026.
- Business Quant data shows SNOA's Operating Margin at 6.31% in Q1 2026, 15.59% in Q4 2025, and 6.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | -0.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.62% |
| Mar 31, 2026 | -6.31% |
| Dec 31, 2025 | -15.59% |
| Sep 30, 2025 | -6.01% |
| Jun 30, 2025 | -27.27% |
| Mar 31, 2025 | -17.47% |
| Dec 31, 2024 | -28.93% |
| Sep 30, 2024 | -23.75% |
| Jun 30, 2024 | -34.59% |
| Mar 31, 2024 | -40.97% |
| Dec 31, 2023 | -26.90% |
| Sep 30, 2023 | -44.23% |
| Jun 30, 2023 | -36.18% |
| Mar 31, 2023 | -38.06% |
| Dec 31, 2022 | -62.30% |
| Sep 30, 2022 | -21.95% |
| Jun 30, 2022 | -21.47% |
| Mar 31, 2022 | -133.16% |
| Dec 31, 2021 | -33.01% |
| Sep 30, 2021 | -25.75% |